The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Antonella Isacchi, Nilla Avanzi et al.|Molecular Oncology|2014Cited by 156
Abstract A243: Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer modelsElena Ardini, Arturo Galvani, Maria Menichincheri et al.|Molecular Cancer Therapeutics|2009Cited by 31
102 Identification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancerElena Ardini, Arturo Galvani, Andrea Borgia et al.|European Journal of Cancer Supplements|2010Cited by 6
NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapiesElena Ardini, Marina Ciomei, Andrea Borgia et al.|European Journal of Cancer|2016Cited by 1
544 Characterization of Potent and Well Tolerated Second Generation FLT3 InhibitorsMarina Ciomei, Andrea Borgia, Nadia Amboldi et al.|European Journal of Cancer|2012Cited by 0